Emergent BioSolutions (EBS) rises 3.7% premarket after announcing it's won a 5-year, $1.25B deal...

|About: Emergent BioSolutions Inc. (EBS)|By:, SA News Editor

Emergent BioSolutions (EBS) rises 3.7% premarket after announcing it's won a 5-year, $1.25B deal to supply its BioThrax anthrax vaccine to the U.S. government. The firm adds BioThrax is the only vaccine licensed by the FDA to prevent anthrax infection.